Needham & Company LLC reiterated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report report published on Monday, AnalystRatings.com reports. They currently have a $84.00 price target on the stock.
Several other equities research analysts also recently weighed in on the stock. Wells Fargo & Co restated a buy rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Zacks Investment Research downgraded Crispr Therapeutics from a hold rating to a sell rating in a research report on Monday, September 30th. BidaskClub lowered Crispr Therapeutics from a strong-buy rating to a buy rating in a report on Friday, December 13th. Canaccord Genuity boosted their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research note on Wednesday, November 20th. Finally, Chardan Capital restated a buy rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $71.38.
Shares of Crispr Therapeutics stock opened at $67.88 on Monday. The company has a market capitalization of $3.76 billion, a PE ratio of -19.73 and a beta of 3.30. The company has a 50-day simple moving average of $63.17 and a two-hundred day simple moving average of $49.95. Crispr Therapeutics has a one year low of $22.36 and a one year high of $74.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, equities analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In related news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at approximately $412,500. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. BSW Wealth Partners purchased a new stake in Crispr Therapeutics in the second quarter valued at $39,000. Balyasny Asset Management LLC acquired a new position in shares of Crispr Therapeutics in the 2nd quarter valued at about $5,165,000. BNP Paribas Arbitrage SA purchased a new stake in shares of Crispr Therapeutics in the second quarter worth about $41,000. Bank of New York Mellon Corp boosted its stake in shares of Crispr Therapeutics by 116.5% in the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after buying an additional 17,810 shares during the last quarter. Finally, First Trust Advisors LP purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $987,000. 49.82% of the stock is currently owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Stock Symbol
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.